Why the study?
Does the SLC22A16 c.146A>G polymorphism influence the pharmacokinetics of doxorubicin in Asian breast cancer patients?
Does the SLC22A16 c.146A>G polymorphism influence the pharmacokinetics of doxorubicin in Asian breast cancer patients?
The SLC22A16 c.146A>G polymorphism exhibits interethnic variation and may contribute to altered doxorubicin pharmacokinetics in Asian breast cancer patients.
No takes yet. Share an insight, caveat, or question.
May influence doxorubicin dosing considerations in Asian patients; leaves open prospective validation of clinical outcomes.
Lal et al. (2007) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: